SSX2 and melanoma: Again, as was found for the SSX2 class II peptides, CD4+ T cells could not recognize melanoma cells directly but were activated by APCs loaded with SSX4 antigen, which suggested that this peptide may not be presented through the endogenous pathway in tumor cells.